Background

Since about 25 years ago, bupropion has been taken as an antidepressant for over 20 years. However, it is typically valid to be used as a 3rd or 4th agent. Due to its unique pharmacology, it leads to inhibit the reuptake of noradrenaline and dopamine and provides potentially a pharmacological augmentation to more conventional antidepressants including selective serotonin reuptake inhibitors (SSRIs). It is administered for treatment of major depressive disorders, treatment of sexual side effects of selective serotonin reuptake inhibitors, and as an aid to smoking cessation. On the other hand, it may result in adverse effects such as nausea, dry mouth, headache, insomnia, dizziness, anxiety, tremor, and constipation. Some case studies have reported that patients are likely to experience dose-related acute dystonic adverse responses to bupropion in the presence or absence of buspirone augmentation. Dystonia, which typically follows the administration of antipsychotics, has been attributed to acute dopamine depletion and basal ganglion-derived gamma synchronization dysfunction. Acute dystonia symptoms are likely to commence in few hours upon beginning or varying antipsychotic drug dosage; nevertheless, a total rate of 90% of symptoms/signs are seen within the first 3–5 days of beginning or increasing dosage.

Abstract

Bupropion is taken as an antidepressant for treatment of major depressive disorders, treatment of sexual side effects of selective serotonin reuptake inhibitors, and as a smoking cessation aid, however, it may result in adverse effects such as nausea, dry mouth, headache, insomnia, dizziness, anxiety, tremor, and constipation. We investigate the case of a 34-year-old woman with bulimia nervosa where acute dystonia was induced by bupropion in 8 months. Following this diagnosis and after normal tests and MRI results, the patient was advised to discontinue bupropion intake. In the follow-up done 2 weeks later, 3 months later, and 6 months later, no signs of acute dystonia was observed. A physician who administers dopamine blocking agents must be aware of the prevalence of and the risk factors for acute dystonia and also the way of prevention and treatment.

Keywords: Anxiety, bupropion induced acute dystonia, bulimia nervosa, dizziness, side effects insomnia

Case Report

Bupropion-induced acute dystonia in a patient with bulimia nervosa: A case report

Parvane Rashidpour, Zahra Poursharif, Mina Ayatollahi, Elham Farzannejad

Department of Psychiatry, Research Center of Addiction and Behavioral Sciences, Shahid Sadoughi, University of Medical Sciences, Yazd, Iran

Abstract

Bupropion is taken as an antidepressant for treatment of major depressive disorders, treatment of sexual side effects of selective serotonin reuptake inhibitors, and as a smoking cessation aid, however, it may result in adverse effects such as nausea, dry mouth, headache, insomnia, dizziness, anxiety, tremor, and constipation. We investigate the case of a 34-year-old woman with bulimia nervosa where acute dystonia was induced by bupropion in 8 months. Following this diagnosis and after normal tests and MRI results, the patient was advised to discontinue bupropion intake. In the follow-up done 2 weeks later, 3 months later, and 6 months later, no signs of acute dystonia was observed. A physician who administers dopamine blocking agents must be aware of the prevalence of and the risk factors for acute dystonia and also the way of prevention and treatment.

Keywords: Anxiety, bupropion induced acute dystonia, bulimia nervosa, dizziness, side effects insomnia

Address for correspondence: Dr. Zahra Poursharif, Department of Psychiatry, Research Center of Addiction and Behavioral Sciences, Shahid Sadoughi, University of Medical Sciences, Yazd, Iran. E-mail: Sanaz.poursharif@gmail.com

Received: 15-06-2020 Revised: 08-09-2020 Accepted: 15-09-2020 Published: 27-02-2021

How to cite this article: Rashidpour P, Poursharif Z, Ayatollahi M, Farzannejad E. Bupropion-induced acute dystonia in a patient with bulimia nervosa: A case report. J Family Med Prim Care 2021;10:1034-6.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKRHPMedknow_reprints@wolterskluwer.com

Access this article online

Quick Response Code:

Website: www.jfmpc.com

DOI: 10.4103/jfmpc.jfmpc_1173_20

© 2021 Journal of Family Medicine and Primary Care | Published by Wolters Kluwer - Medknow
BN cases who have been identified in a national community survey presented as an additional psychiatric disorder, and common comorbidities were mood, anxiety, impulse control, and substance misuse disorders. Due to the non-significant number of studies conducted in this regard, we have investigated a case presentation where bupropion-induced acute dystonia was seen in a patient with BN.

Case Presentation

Upon assurance of patient’s consent to participate in the study by signing the written consent form, from 8 months before the investigation, a 34-year-old married female patient (a medical staff) with a history of BN and weight and height of 52 kg and 164 cm, respectively, had been initially treated with slow-release bupropion at an initial dose of 75 mg due to sadness and impatience (mostly in the mornings) as well as hypersomnia and overeating. The mentioned dose reached 300 mg within 2 weeks. The patient was simultaneously taking 300 mg of bupropion with 20 mg of propranolol and 10 mg of chlordiazepoxide 10 at noon. The patient stated that her appetite would be decreased only in case of taking the three pills simultaneously. During the 8 months, the patient lost 6 kg of weight. Accordingly, after a while, she gradually increased the dose of slow-release bupropion to 450 mg/day due to the persistence of weight. Following such an increase in bupropion dose from 300 mg to 450 mg, after 3 days, she was suffering from painful muscular contractions in the legs, thighs, respiration, and swallowing and also abdominal pain, drooling, and suffocation feeling. She then referred the emergency department and received 10 g of diazepam intramuscularly. However, no change in symptoms made her suspected to be with acute dystonia. To this end, she was treated with 2 mg of biperiden intravenously, and then symptoms were resolved shortly. After 3 days, with the beginning use of 450 mg of bupropion again, the symptoms of acute dystonia begin to recur, which is ameliorated by the injection of biperiden. Two days later, the patient took 300 mg of bupropion again, which also led to acute dystonia symptoms.

The patient stated a history of BN disorder since the age of 15, during which she had used different calorie diets, fluoxetine tablets, ritalin tablets, diethylpropion hydrochloride tablets, laxatives, and bisacodil suppositories as well as the intragastric balloon method. Besides, the patient stated no history of head trauma, convulsions, fever, and drug use. There was also no history of psychiatric disorders and physical diseases in her family.

Normal complete blood cell counts, calcium and magnesium levels, vitamin B12 levels, folic acid levels, and ferritin levels were reported. The patient’s brain magnetic resonance imaging (MRI) also reported normal conditions. Accordingly, following diagnosis of bupropion-induced acute dystonia, the patient was advised to discontinue bupropion intake. In the follow-ups done 2 weeks later, 3 months later, and 6 months later, no signs of acute dystonia were observed.

Discussion

The management of a 34-year-old female with BN becomes more complicated if she is diagnosed with bupropion-induced acute dystonia, as well. She had normal conditions as reported in tests and MRI results.

Interestingly, about 1% of females are likely to have BN which is identified according to an intense preoccupation with body weight, uncontrolled binge-eating episodes, and use of extreme actions to deal with the feared effects of overeating.

Besides, the complexities get higher when people with BN may be of normal weight, so the diagnosis of BN will be more difficult. Obesity points to both an increased risk of BN and a worse prognosis, as having personality disorders and substance misuse. After 10 years, about half of people with BN will have recovered fully, one-third will have made a partial recovery, and 10% to 20% will still have symptoms.

In most cases, acute dystonia is seen within 96 h of commencing treatment based on antipsychotic medications or followed by a considerable increase in the dose of such drugs. Sometimes, acute dystonia is diagnosed during maintenance treatment with a depot antipsychotic within a few days after the depot has been administered. However, in our case, a female with BN was diagnosed to have acute dystonia which was induced by bupropion. To our knowledge, such a case was not studied formerly but the findings indicated that discontinuation of bupropion is the best solution to stop the recurrence of acute dystonia. Moreover, some case studies have shown that the increased dose of bupropion may also induce acute dystonia. Taking bupropion along with a serotonin reuptake agent including either buspirone or SSRIs can lead to acute dystonia.

Regarding the treatment of acute dystonia, the common approaches have typically been oral medications, counseling and education, and botulinum toxin injections as well as plenty of surgical methods. Besides, those supposed to experience acute dystonia are recommended strongly to be assessed with Wilson’s disease, catatonia, tetanus, hypocalcaemia, encephalitis as well as conversion and malingering disorders.

In the case presented by Derweiler and Harpold, the authors argue that such patients are likely to experience dose-related acute dystonic adverse responses to bupropion in the presence/absence of buspirone. Dystonia cases, which typically follow the prescription of antipsychotics are regularly associated by depletion of acute dopamine as well as basal ganglion-derived γ synchronization dysfunction. Signs and symptoms of acute dystonia are likely to commence in hours of beginning or varying the dosage of an antipsychotic drug; nevertheless, 90% of symptoms are seen within the first 3 to 5 days of dosage increasing/beginning.
Besides, in another similar case, \cite{9} it was shown that patients suffering from acute dystonia are also likely to experience dose-related acute dystonia as negative responses to bupropion's extent release (ER).

In addition, Elyasi and Mahtiyan\cite{13} discussed a 34-year-old male patient suffering from a painful neck spasm which was sufficient to wake him up and dystonic distortion followed by using just a single dose of bupropion as much as 75 mg. The patient was diagnosed with obsessive-compulsive disorder (OCD) and treated with 60 mg fluoxetine. For the patient, bupropion was also included in the medications due to the sexual side effects that resulted from the fluoxetine. They concluded that dystonic symptoms must be considered when bupropion is mixed with additional medications that influence the serotonin reuptake.

Similarly, Wang et al.\cite{14} reported a patient suffering from major depression and acute dystonia in two episodes, caused by abrupt discontinuation of bupropion. Episode 1 was seen when medicament varied abruptly from bupropion to duloxetine. This patient was asked to do nothing by mouth (i.e., Latin Nil Per Os [NPO]) due to panendoscopic examination. As a result, episode 2 began followed by suspension of the patient from two doses of bupropion. The symptoms including trismus, dysphagia, and torticollis in both episodes were resolved upon the reinstitution of bupropion or injection of biperiden.

**Conclusion**

Acute dystonia induced by medication like bupropion is likely to be a side effect of treatment with antipsychotic drugs and other drugs, and it may occur at an early phase of treatment. Acute dystonia is often frightening and may seriously disturb the relationship between the doctor and the patient. Therefore, a physician who administers dopamine blocking agents must be aware of the prevalence of and the risk factors for acute dystonia and also the way of prevention and treatment.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK. Bupropion: A systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol 2016;6:99-144.
2. Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 2006;12:178-207.
3. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004;6:159-66.
4. Yasin W, Ahmed SI, Gouthro RV. Does bupropion impact more than mood? A case report and review of the literature. Cureus 2019;11:e4277.
5. Detweiler MB, Harpold GJ. Bupropion-induced acute dystonia. Ann Pharmacother 2002;36:251-4.
6. Hall I, Le Grange D. Bulimia nervosa in adolescents: Prevalence and treatment challenges. Adolesc Health Med Ther 2018;9:11-6.
7. Hay PJ, Claudino AM. Bulimia nervosa. BMJ Clin Evid 2010;2010:1009.
8. Oyewole A, Adelufosi A, Abayomi O. Acute dystonic reaction as medical emergency: A report of two cases. Ann Med Health Sci Res 2013;3:453-5.
9. van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ 1999;319:623-6.
10. Wasif N, Wasif K, Saif MW. Bupropion-induced acute dystonia with dose escalation and use of naranjo nomogram. Cureus 2017;9:e1157.
11. Jinnah HA, Factor SA. Diagnosis and treatment of dystonia. Neurol Clin 2015;33:77-100.
12. Sarisoy S, Ozyurek H, Sarisoy G. Oromandibular dystonia associated with sertraline in an adolescent patient. Bull Clin Psychopharmacol 2012;22:83-5.
13. Elyasi F, Mahtiyian E. Acute dystonia after single dose of bupropion. Indian J Psychol Med 2016;38:460-2.
14. Wang HY, Chou WJ, Huang TY, Hung CF. Acute dystonia resulting from abrupt bupropion discontinuation. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:766-8.